Skip to main content
. Author manuscript; available in PMC: 2009 Mar 14.
Published in final edited form as: Mol Cell. 2008 Mar 14;29(5):541–551. doi: 10.1016/j.molcel.2007.12.023

Figure 4. Effect of PBA treatment on UPR in TSC1- and TSC2-deficient cells.

Figure 4

(A) PERK (Thr980) phosphorylation after 4-PBA (10 mM) treatment for 24 hours in Tsc1−/− MEFs. Phospho-S6K-1 (Thr389), total S6K-1, and phospho-S6 (ser235/236) levels were analyzed with or without 4-PBA treatment in Tsc1−/− MEFs, shown in triplicate. (B) mRNA levels of CHOP, XBP-1s and GRP78 in Tsc1+/+ and in Tsc1−/− cells either in the presence or absence of 4-PBA (10mM) after 24 hours incubation. (C) PERK phosphorylation (Thr980), phospho-S6K-1 (Thr389), and total S6K-1, phospho-S6 (ser235/236) levels with or without 4-PBA treatment in Tsc2−/− (+VEC) MEFs and in their controls Tsc2−/− (+TSC2) cells. (D) CHOP, XBP-1s and GRP78 gene expression levels in WT (+TSC2) and Tsc2−/− (+VEC) cells treated with PBA (10mM) or PBS for 24 hours. Data are mean ± SEM of triplicates.